Pieris Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Palvella Therapeutics

03/11/2021 10:57

* Pieris Pharmaceuticals Inc  PIRS.OQ  reported a quarterly
adjusted loss of 24 cents​​ per share for the quarter ended in
September. The mean expectation of three analysts for the
quarter was for a loss of 24 cents per share.
* Revenue rose 38% to $4.06 million from a year ago;  analysts
expected $5.32 million. 
* Pieris Pharmaceuticals Inc's reported EPS for the quarter was
a loss of 24 cents​.
* The mean earnings estimate of analysts was unchanged in the
last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Pieris Pharmaceuticals Inc shares had fallen by 8.1% this
quarter and gained 90.0% so far this year.
* The company reported a quarterly loss of $16.54 million.
* Wall Street's median 12-month price target for Pieris
Pharmaceuticals Inc is $8.50 
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
This summary was machine generated November 3 at 10:57 a.m.
 ​All figures in US dollars unless otherwise stated